A Nanoparticle’s Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations

SIMPLE SUMMARY: Traditional cancer therapeutics suffer from off-target toxicity, limiting their effective dose and preventing patients’ tumors from being sufficiently treated by chemotherapeutics alone. Nanomedicine is an emerging class of therapeutics in which a drug is packaged into a nanoparticle...

Descripción completa

Detalles Bibliográficos
Autores principales: Milligan, Joshua J., Saha, Soumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996837/
https://www.ncbi.nlm.nih.gov/pubmed/35406513
http://dx.doi.org/10.3390/cancers14071741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996837/
https://www.ncbi.nlm.nih.gov/pubmed/35406513
http://dx.doi.org/10.3390/cancers14071741

Ejemplares similares